Pelareorep Shows 33% Response Rate in KRAS-Mutant Colorectal Cancer, Tripling Standard-of-Care Outcomes
Key Insights
Pelareorep combined with standard-of-care therapy achieved a 33% objective response rate in second-line KRAS (search)-mutant microsatellite-stable colorectal cancer (search), compared to 6-11% with standard therapy alone.
The investigational immunotherapy more than doubled both progression-free survival and overall survival compared to bevacizumab plus FOLFIRI (search) treatment regimen.
Translational analysis revealed pelareorep enhanced KRAS (search)-mutant-specific T-cell populations, providing mechanistic support for its precision immunotherapy approach.
Pelareorep (Reolysin) in combination with standard-of-care therapy demonstrated remarkable efficacy as a second-line treatment for patients with KRAS (search)-mutated metastatic microsatellite-stable (MSS) colorectal cancer, achieving response rates that triple historical benchmarks, according to findings from Oncolytics Biotech.
The investigational immunotherapy achieved a 33% objective response rate (ORR) when combined with bevacizumab (Avastin) plus FOLFIRI (search) (leucovorin, 5-fluorouracil, and irinotecan) in patients with KRAS (search)-mutated MSS colorectal cancer, compared to the well-established historical ORR of approximately 6-11% for bevacizumab plus FOLFIRI alone in second-line metastatic colorectal cancer (search).
Survival Benefits Exceed Standard Care
Beyond response rates, the pelareorep combination demonstrated substantial survival advantages. Patients receiving the investigational regimen achieved a median overall survival of 27.0 months and progression-free survival of 16.6 months, compared to 11.2 months and 5.7 months respectively with standard-of-care therapy alone.
These findings emerged from the phase 1 REO 022 trial (NCT01274624), which enrolled patients with KRAS-mutated metastatic colorectal cancer (search) and assigned them to receive four escalating doses of pelareorep plus standard-of-care therapy. Pelareorep was administered as a 1-hour intravenous infusion on days 1-5 of each 4-week cycle, combined with biweekly bevacizumab at 5 mg/kg and FOLFIRI (search) chemotherapy.
Mechanistic Insights Support Precision Approach
A separate translational analysis of paired tumor biopsies revealed that treatment with pelareorep led to a notable increase in KRAS (search)-mutant-specific T-cell populations, indicating the therapy may directly enhance anti-tumor immune recognition in this genetically defined subgroup. These findings provide biological support for pursuing pelareorep as a precision immunotherapy for a patient population that rarely benefits from checkpoint inhibitors or other immunotherapies.
"These results are extremely encouraging. Achieving a 33% ORR in KRAS (search)-mutant MSS colorectal cancer is highly unusual in this setting and warrants immediate further study," said Sanjay Goel, MD, MS, professor of Medicine, Division of Medical Oncology, and Section of Solid Tumor at Rutgers Cancer Institute of New Jersey. "The translational findings strengthen the mechanistic rationale behind the clinical activity we are observing. I am eager to move this program into a controlled study to validate the signal and help bring a much-needed therapeutic option to this patient population."
Addressing an Underserved Market
KRAS (search)-mutant MSS colorectal cancer represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer. The condition affects patients who have limited therapeutic options, particularly in the second-line setting where current standard-of-care treatments show modest efficacy.
"Pelareorep has clearly demonstrated the potential to become a transformational new treatment option in this underserved setting," said Jared Kelly, chief executive officer of Oncolytics Biotech. "With translational data supporting its unique activation of KRAS (search)-specific T cells, pelareorep has delivered a 33% response rate in KRAS-mutant, MSS colorectal cancer."
Next Steps and Regulatory Path
The clinical and mechanistic data support advancing pelareorep into a controlled study in second-line KRAS (search)-mutant MSS metastatic colorectal cancer (search). Oncolytics expects to initiate this study following consultation with key opinion leaders and regulatory authorities. The company plans to sponsor the study directly rather than pursuing an investigator-sponsored trial, providing greater control over data and analytical rigor to support potential regulatory submissions.
The phase 1 trial's primary endpoints focused on dose-limiting toxicities and pharmacokinetic parameters of irinotecan and 5-fluorouracil when combined with pelareorep. Secondary endpoints included objective response rate, clinical benefit rate, progression-free survival, overall survival, and safety. Eligible patients were 18 years and older with histologically confirmed colon or rectal cancer (search), radiologically measurable metastases, and confirmed KRAS (search)-mutated disease who had received prior oxaliplatin-based chemotherapy.